

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

CASE RECORD FORM.

STUDY TITLE:

Comparative Evaluation of Antidiabetic Activity of Acarbose, Miglitol alone and in combination with Salacia Species in patient of Type – Diabetic Mellitus.

STUDT DESIGN:

Single blind, Randomized, parallel group, comparative, prospective trial.

PROTOCOL NUMBER:

SPONSORS (IF ANY)

INVESTIGATOR:

DEMOGRAPHICS

Patients initials: -----		
Date of birth: --/ --/ ----- DD MM YEAR	Age: (Years) <input type="text"/>	Sex (M/F): <input type="text"/>
Height (Cm):	Weight (kg):	
Informed consent form understood and signed	Yes <input type="text"/>	On ----- (dd/mm/yyyy)

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

INCLUSION CRITERIA:

Sr.No	Criteria	Yes	No
1.		<input type="checkbox"/>	<input type="checkbox"/>
2.		<input type="checkbox"/>	<input type="checkbox"/>
3.		<input type="checkbox"/>	<input type="checkbox"/>
4.		<input type="checkbox"/>	<input type="checkbox"/>
5.		<input type="checkbox"/>	<input type="checkbox"/>

If the answer to all the above questions is “YES”, then include the patient

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

EXCLUSION CRITERIA:

Sr.No	Criteria	Yes	No	Not applicable
1.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

If the answer to all the above questions is “NO”, then include the patient

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

MEDICAL HISTORY (if applicable)

Sr.No	Long term illness	Duration	Treatment		
			Completed	Under treatment	Not taken

SURGICAL HISTORY (if applicable)

Sr.No	Major surgical procedure	Indication	Duration after surgery

Investigator Signature

Date

Depending upon the number of visits / follow up the visit schedule should be made and may include.....

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

PHYSICAL EXAMINATION (PER STUDY-SCREENING)

<u>General Appearance & Nutrition Status</u>	Normal	abnormal	Not done	Comments
Skin				
Head, Neck & Thyroid				
Lymph nodes				
Eyes				
Ear, Nose & Throat				
Respiratory System				
Cardiovascular System				
Gastrointestinal system (GERD etc)				
CNS				
Musculoskeletal System				
Others				

Are there any abnormal physical findings present? If yes, please make note of it.

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

VITALS

Pulse rate	-----/ min
Respiratory	-----/ min
Heart rate	-----/ min
Temperature	-----/ min
Blood pressure	-----/ min

Investigator Signature

Date

LABORATORY DATE (which ever applicable)

Investigation	Normal values	Value reported
HEMATOLOGY		
Hemoglobin		
Red Blood Cell		
WBC with differential count		
Absolute neutrophil count		
Hematocrit		
Mean Corpuscular Volume (MCV)		
Mean Corpuscular Volume Concentration (MCVC)		
Platelets		
SERUM CHEMISTRY		
Blood Urea Nitrogen (BUN)		
Creatinine		
AST (SGOT) μ /l		
ALT (SGPT) μ /l		
Albumin		
Alkaline phosphatase		

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Total bilirubin		
Bicarbonate		
LDH		
Glucose fasting		
Glucose post prandial		
Total protein		
Sodium		
Potassium		
Calcium		
Chloride		
Cholesterol		
Serum pregnancy test (in women of childbearing potential)		

Comments on all clinical significant laboratory values outside normal range(s):

Investigator Signature

Date

CONCOMITANT MEDICATION (if applicable)

(The presence of underlying conditions or past surgeries can necessitate the use of various medications like corticosteroids, chemotherapy or anti-infective medications. if present, a note of the same should be made as follows).

Sr. No	NAME DRUG	ROUTE OF ADMINISTRATION	TOTAL DAILY DOSE	INDICATION	DURATION OF DRUG THERAPY	
					FROM	TO

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Note:

- **Brand name of the medication preferred over generic name.**
- **Enter only one medication per section. if more than one medication is used for one indication, list all of them individually in separate section.**

Investigator Signature

Date

<u>Electro-Cardio Graph (ECG) (Pre-study-Screening)</u>	
Date : (dd/mm/yyyy)	Time:
Findings:	
Investigator`s comments	

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

<u>AE/SAE Reporting form</u>			
Patient details:			
Initials & other relevant identifier: (Hospital/OPD record no. etc)			
Gender:	Weight in Kg:	Date of birth (dd/mm/yyyy)	Height in cm:
Suspected drug(s):			
Generic name of the drug			
Indication(s) for which suspect drug was prescribed or tested			
Dosage form and strength			
Daily dose and regimen (specify units ex. mg, ml, mg/kg)			
Route of administration			
Starting Date & time of day (dd/mm/yyyy) (am/pm)			
Stopping date & time of day (or)duration of treatment (dd/mm/yyyy) (am/pm)			
Details of adverse event: (Mention in detail about the medical event and if possible diagnosis for that condition)			

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Expectedness:		
Expected:		Unexpected:
Intensity: (Investigator discretion/guidelines)		
Mild:	Moderate:	Severe:
Assessment: : (Investigator discretion/guidelines)		
Serious:		Not-serious:
Relationship to study medication:		
Unrelated		
Un likely		
Possibly		
Probably		
Definitely		
Un known		
Other attributable causes		
Other causes:		
Primary underlying disease		
Study indication		
Concomitant medication		

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Study participation	
Other cause (Specify)	
Action taken:	
Yield/out come:	
Complete recovery (with out sequel)	
Recovered (with sequel)	
Ongoing	
Ongoing at the time of death	

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Death:	
Unknown:	
Others (specify)	
Duration:	
Start Date: (dd/mm/yyyy)	Stop Date: (dd/mm/yyyy)
Details of the Investigators:	
Details of Investigators	
Name:	
Address:	
Telephone no.	
Profession:	
Signature:	

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Global Assessment:

Efficacy:

Investigator

Excellent Good Poor

Remarks:

Efficacy:

Patient

Excellent Good Poor

Remarks:

Tolerability:

Investigator

Excellent Good Poor

Remarks:

Patient

Excellent Good Poor

Remarks:

Investigator Signature **Date**

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

STUDY COMPLETION

Study completed Yes No

If yes, Date of Study Completion: -----/-----/-----
DD MM YEAR

If No, Date of Withdrawal: -----/-----/-----
DD MM YEAR

The Reasons for Withdrawal:

- No response
- Other illness
- Adverse event
- Lost of follow up of patient
- Other
- Death

In case of death (if any)

a) Date of death: _____

b) Cause of death: _____

c) Possible causal relationship with the trial: _____

Any other comments:

INVEST GATORS STATEMENT:

The data generated and reproduced of above is of authenticate and genuine to my knowledge.

Investigator Signature

Date

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

CASE RECORD FORM

INCLUSION CRITERIA:

Please read carefully and tick (√) in the appropriate box

	Yes	No
A. Age: 18 years of age or older	<input type="checkbox"/>	<input type="checkbox"/>
B. Patients with Type 2 Diabetes mellitus with PPG >200 Mg/dl and HbA ₁ C >7%	<input type="checkbox"/>	<input type="checkbox"/>
C. Patient ready to give informed consent to participate in the study after explaining about the drug and the Study	<input type="checkbox"/>	<input type="checkbox"/>

EXCLUSION CRITERIA:

Please read carefully and tick (√) in the appropriate box

	Yes	No
A. Clinically significant deviation from normal in physical examination, laboratory parameters, ECG, as evaluated by the Clinical Investigator	<input type="checkbox"/>	<input type="checkbox"/>
B. <u>Clinically significant coexisting diseases, including:</u>		
1. Clinically significant cardiovascular disease, including a history of myocardial infarction.	<input type="checkbox"/>	<input type="checkbox"/>
2. Clinically significant gastrointestinal disease, including active peptic ulcers, inflammatory bowel disease, intestinal obstruction etc.	<input type="checkbox"/>	<input type="checkbox"/>
3. Impaired liver function/ renal function/ thyroid function tests	<input type="checkbox"/>	<input type="checkbox"/>
4. Patients with Insulin - dependent diabetes mellitus or those who have taken insulin in the past	<input type="checkbox"/>	<input type="checkbox"/>
5. Patients with rapidly progressive retinopathy, neuropathy, nephropathy.	<input type="checkbox"/>	<input type="checkbox"/>
C. Presence of any acute illness.	<input type="checkbox"/>	<input type="checkbox"/>
D. H/o sensitivity to study drugs i.e. Acarbose, Miglitol, Voglibose.	<input type="checkbox"/>	<input type="checkbox"/>

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

- E. History of alcohol, barbiturate, marijuana, or polydrug abuse.
- F. History of antidiabetic medication other than study drugs during past 3 months
- G. Concomitant medication affecting glucose homeostasis such as glucocorticoids within 8 weeks.
- H. Participation in other investigational drug studies within 8 weeks before the start of the study.
- I. Subjects who are unlikely to be compliant with the protocol requirements.
- J. Pregnant or lactating females.

PATIENT DETAILS

Reg. No. _____ **Date:** _____

Name: _____

Age: _____ **Sex:** _____

Address: _____

Occupation: _____

H/o Type 2 Diabetes Mellitus since _____ years, taking following medications:

1. _____
2. _____
3. _____
4. Past h/o medical or surgical illness:

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

GENERAL EXAMINATION

	Visit 1	Visit 2	Visit 3
	__/__/__	__/__/__	__/__/__
Temperature (deg F)			
Pulse / min			
Respiratory rate / min			
Blood pressure (mmHg)			
Heart Rate/min			
Weight (kg)			

SYSTEMIC EXAMINATION

	Visit 1	Visit 2	Visit 3
	__/__/__	__/__/__	__/__/__
Respiratory system			
Cardiovascular system			
Central nervous system			
Per abdomen			

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Study group: _____

Laboratory Investigations:

Hemogram:

	Visit 1	Visit 2	Visit 3
	__/__/__	__/__/__	__/__/__
Hemoglobin (gm %)			
Total WBC count			
ESR (mm at end of 1 hour)			

Blood sugar profile:

	Visit 1	Visit 2	Visit 3
	__/__/__	__/__/__	__/__/__
Fasting blood sugar (mg %)			
Post prandial blood sugar (mg %)			
HbA ₁ C (%)			

Liver function tests:

	Visit 1	Visit 2	Visit 3
	__/__/__	__/__/__	__/__/__
SGOT (U/L)			
SGPT (U/L)			
S. bilirubin (mg %)			

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Renal function tests:

	Visit 1	Visit 2	Visit 3
	___/___/___	___/___/___	___/___/___
S. Creatinine (mg %)			

Adverse drug reactions monitoring

Did the patient experience any adverse event? Yes No

If yes, then please fill the details as given below

Sr.no	Adverse event (Specify)	Start date dd/mm/yy	End date dd/mm/yy	Severity*	Relation to drug**	Action taken	Out Come of the event***

*Record severity as 0- absent , 1- Mild , 2- Moderate , 3- Severe

** Grading as 0- None; 1- Remote; 2- Possible; 3- Not assessable

***Grading as 1- Resolved ; 2- Improved ; 3- Unchanged ; 4 – Worsened ; 5- Death

Patient status

Completed the study: YES/NO

If **NO** then,

Withdrawn before completion due to

Patient's desire :

Severe side effects:

Remarks: -----

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

PROFORMA

PATIENTS NAME;

CONSULTANT'S NAME:

NAME OF HOSPITAL:

DATE OF ADMISSION:

SEX:

AGE:

WEIGHT:

HEIGHT:

BMI:

ADRESS:

CONTACT NUMBER:

- **HOME:**
- **OFFICE:**
- **MOBILE:**

E-MAIL:

OCCUPATION:

SOCIAL HISTORY:

Nonalcoholic/ Alcoholic @ the age.

Nonsmoker /smoker @ the age.

Vegetarian / non-vegetarian.

PHYSICAL EXAMINATION

A General Physical Examination is to be done to answer the following questions.
(Were there any abnormal physical findings present? If yes, Please make note of it in the comments)

General Appearance & Nutrition	Yes / No	Comments
Skin		
Head, Neck & Thyroid		
Lymph nodes		
Eyes		
Ear, nose & throat		
Respiratory System		
Cardiovascular System		
Abdomen		
CNS		
Musculoskeletal System		

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

Vitals (Record the vitals)

Blood Pressure SBP -----/ ----- mmHg; DBP -----/ ----- mmHg;

Pulse -----/min

Temperature ----- deg F

Heart Rate ----- / min

Respiratory Rate -----/ min

LIST OF INVESTIGATIONS

INVESTIGATION	Visit 1	Visit 2 (week 12)	Visit 3 (week 24)
1. Hb %			
2. TLC			
3. Total Bilirubin (mg/ 100ml)			
4. SGOT (AST) / μ l			
5. SGPT (ALT) / μ l			
6. Sr Creatinine	√		
7. Blood Pressure			
8. Fasting Blood Glucose			
9. PP Blood Glucose			
10 HbA _{1c} ,			
11. Sr Triglycerides			
12. BMI			

Note : Hb% Hemoglobin; TLC=Total Leucocyte Count; SGOT=Glutamy1 Oxalo Transferase;
SGPT=Serum Glutamy1 Phosphory1 Transferase; PP=Post prandial BMI =Body mass index

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

ON EXAMINATION:

Sr. No.	Date	Time	Blood glucose level

PAST MEDICAL HISTORY:

PAST MEDICATION HISTORY:

PRESENT COMPLAINTS:

DIAAGNOSTIC TESTS PERFORMED:

Sr. NO.	Date	Test	Normal range	Observed value.
1				

OTHER TESTS PERFORMED:

CRF	Protocol number
ENROLLMENT NUMBER:	PATIENTS INITIALS:

MEDICATION DETAILS:

Sr. no.	Medication	Compositions	Dose and Frequency	Rout	Date

COMMENTS:

DATE: